Montemayor SD, Salas AJC

Language: Spanish
References: 19
Page: 45-48
PDF size: 88.85 Kb.

ABSTRACT

Palmoplantar pustular psoriasis (PPP) is a chronic, recurrent disease characterized by pustular lesions on palms and soles. There is an intraepidermal pustule with polymorphonuclear leukocytes and spongiosis on the surrounding epidermis. The cause is unknown and it has been associated to a decreased antileukoprotease (SKALP, elafine) activity, which results in the formation of pustular lesions. Management is limited and most of the patients have a poor response to treatment. We report a 34 year-old male with PPP. We review histopathologic findings and treatment options according to reviewed literature.

REFERENCES

1. Schon M, Boehncke WH. “Psoriasis. Review article”. N Engl J Med 2005; 352: 1899-1912.

2. Kahn MF, Chamot AM. “SAPHO syndrome”. Rheum Dis Clin North Am 1992; 18: 225.

3. Kaperczyk A, Freyschmidt J. “Pustulotic arthrosteitis: spectrum of bone lesions with palmoplantar pustulosis”. Radiology 1994; 191: 207-211.

4. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. “Chapter 21: pustular eruptions of palms and soles”. En Fitzpatrick’s dermatology in general medicine, 7a ed., McGraw-Hill, Nueva York, 2008, 215-218.

5. Iglesias L, Guerra A, Ortiz PL. “Enfermedades eritematoescamosas y pustulosas”. En Tratado de dermatología, 2a ed., McGraw-Hill Interamericana, Madrid, 2004, 481-482.

6. Kuijpers AL, Zeeuwen PL, Jongh GJ, Kerkhof PC, Alkemade HA, Schalkwijk J. “Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation?” Arch Dermatol Res 1996; 288(11): 641-647.

7. Hagforsen E, Mustafa A, Lefvert AK, Nordlind K, Michaëlsson G. “Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?” Acta Derm Venereol 2002; 82: 341.

8. Habif, TP. “Psoriasis and other papuloescamous diseases”. En Habif. Clinical Dermatology, 4a ed., Mosby, Filadelfia, 2004, 209-265.

9. Langley RGB, Krueger GG, Griffiths CEM. “Psoriasis: epidemiology, clinical features, and quality of life”. Ann Rheum Dis 2005; 64: 18-23.

10. Yamamot T, Yokozeki H, Tsuboi R. “Koebner´s phenomenon associated with palmoplantar pustulosis”. JEADV 2007; 21: 977-1010.

11. Lever, WF, Schaumburg G. “Chapter 8. Noninfectious erythematous, popular, and squamous diseases”. En Histopathology of the skin, 7a ed., Liippincott, Filadelfia, 1990, 163-164.

12. Michaelsson G, Gustafsson K, Hangforsen E. “The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking”. J Am Acad Dermatol 2006; 54: 737-738.

13. Bruner CR, Feldman SR, Ventrapgrada M, Fleischer AB. “A systemic review of adverse effects associated with topical treatments for psoriasis”. Dermatology Online J 2003; 9(1).

14. Marsland AM, Chalmers RJ, Hollis S, Leonardo-Bee J, Griffiths CE. “Interventions for chronic palmoplantar pustulosis”. Cochrane Database System Rev 2006; (1): CD001433.

15. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. “Low-dose acitretin is associated with fewer adverse events than highdose acitretin in the treatment of psoriasis”. Arch Dermatol 2006; 142: 1000-1004.

16. Barclay L. “Low-vs-high-dose acitretin is better tolerated in psoriasis patients”. Arch Dermatol 2006; 142: 1000-1004.

17. Reitamo S, Erkko P, Remitz A, Lauerma AI, Montonen O, Harjula K. “Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study”. Br J Dermatol 2002; 139: 997-1004.

18. Ravi BK, Kaur I, Kumar B. “Topical methotrexate therapy in palmoplantar psoriasis”. Indian Dermatol Venereol Leprol 1999; 65: 270-272.

19. Reitamo S, Erkko P, Remitz A. “Cyclosporin for palmoplantar pustulosis”. J Autoimmun 1992; 5(supl A): 285-287. 48 Dermatología Cosmética, Médica y Quirúrgica Volumen 7 / Número 1 / enero